Aclaris therapeutics provides 2023 outlook

Wayne, pa., jan. 06, 2023 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023.
ACRS Ratings Summary
ACRS Quant Ranking